Dfn-15
Chronic Low-back Pain
Laboratorios Silanes S.A. de C.V.Phase 3Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Chronic Low-back Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Uskudar University | Phase 4 | BB |
Duloxetine University of North Carolina, Chapel Hill | Phase 4 | BB |
LEVODOPA Northwestern University | Phase 2 | CCC |
carbidopa Northwestern University | Phase 2 | CCC |
Naproxen Northwestern University | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →